Editor’s Note: At ESMO 2026, the INTerpath-001 study—the first Phase III trial of a personalized mRNA cancer vaccine to report positive results worldwide—was presented as the congress’s first Late-Breaking Abstract (LBA1), generating considerable excitement. The announcement was met with 34 seconds of sustained applause, marking a milestone moment for cancer immunotherapy.

The study showed that, in the adjuvant treatment of patients with resected high-risk cutaneous melanoma, the personalized neoantigen therapy intismeran combined with pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared with pembrolizumab alone. This represents an important breakthrough in the clinical development of personalized cancer vaccines.

However, many questions remain regarding how this innovative strategy can be extended to different melanoma subtypes, particularly acral and mucosal melanoma, which are more common among Chinese patients.

At ESMO 2026, Oncology Frontier interviewed Professor Jun Guo from Peking University Cancer Hospital. Drawing on the findings of INTerpath-001, Professor Guo shared his perspectives on the clinical value and technological development of personalized mRNA cancer vaccines, as well as their potential applications in Chinese patients with melanoma.


Oncology Frontier: ESMO 2026 presented the first positive Phase III results worldwide for a personalized mRNA cancer vaccine. In light of the impressive findings from INTerpath-001, how do you view the clinical value of this study? What impact could it have on melanoma treatment?

Professor Jun Guo: mRNA cancer vaccines have finally achieved a major success in a Phase III clinical trial. After Professor Georgina Long completed her presentation, the applause in the auditorium continued for a long time, reflecting the widespread attention this achievement received. It represents another important step forward in humanity’s efforts to explore new approaches to cancer treatment.

The success of this study is remarkable: it marks the first successful demonstration of a personalized mRNA vaccine in a Phase III trial. Previously, whether in targeted therapy or immunotherapy, the drugs we used were manufactured through industrialized production processes. The success of this personalized mRNA cancer vaccine is fundamentally different. It represents the culmination of a century of accumulated knowledge and exploration across multiple fields, including molecular biology and immunology.

In the past, we explored various cancer vaccines, but none had achieved success in a Phase III clinical trial. INTerpath-001 has achieved this breakthrough for the first time, and I believe this is inseparable from the rapid development of science and technology in recent years.

Through whole-genome sequencing of tumor tissue, we can identify tumor neoantigens. With the support of bioinformatics, computer science, and artificial intelligence, we can analyze and screen these neoantigens, design and synthesize the corresponding mRNA sequences, and ultimately produce a personalized vaccine for each patient.

At present, intismeran in INTerpath-001 is primarily being used as adjuvant treatment for cutaneous melanoma. Its manufacturing process remains relatively complex. First, tumor tissue must be obtained, followed by whole-genome sequencing and bioinformatics analysis to identify neoantigens. The corresponding mRNA must then be designed and manufactured before the vaccine can be administered to the patient.

The entire process takes considerable time and is relatively expensive. These are practical challenges that will need to be addressed before the treatment can be widely incorporated into clinical practice. Nevertheless, mRNA vaccine intismeran combined with pembrolizumab has outperformed the current standard of pembrolizumab monotherapy, marking a solid step forward in the adjuvant treatment of melanoma.

I believe future research into mRNA cancer vaccines will not be limited to melanoma. It may soon expand to other cancers, including non-small cell lung cancer and renal cancer, with corresponding clinical studies gradually getting underway. I have high expectations for this development.

At least in the field of adjuvant melanoma treatment, we now have a new therapeutic tool. This achievement has been made possible by long-term advances in immunology, molecular biology, genetics, engineering, computer science, and other disciplines. It represents a new level of human scientific ingenuity and technological innovation, and is certainly something worth celebrating.


Oncology Frontier: In your view, what is the most important breakthrough achieved by INTerpath-001? How does this innovative treatment strategy differ from conventional immunotherapy in terms of mechanism, efficacy, and clinical practice?

Professor Jun Guo: Looking back at the development of adjuvant treatment for melanoma, interferon was the earliest treatment used. Subsequently, immunotherapeutic agents such as PD-1 and CTLA-4 monoclonal antibodies became available, with PD-1 inhibitors eventually establishing themselves as the standard of care for adjuvant melanoma treatment.

Since then, there have been relatively few major breakthroughs in this field. The success of this Phase III study combining an mRNA vaccine with a PD-1 inhibitor represents a new advance in the adjuvant treatment of cutaneous melanoma and may offer a new treatment option in the future.

However, INTerpath-001 also raises several questions that deserve further consideration.

First, as neoadjuvant treatment continues to develop, an increasing number of patients with melanoma are receiving neoadjuvant therapy, substantially changing the clinical landscape of traditional adjuvant treatment. In the future, can mRNA vaccines be integrated with neoadjuvant treatment, and how should they be combined? Should the vaccine be used alone or in combination with other treatments? Should it be administered only in the neoadjuvant setting, or throughout the entire neoadjuvant and adjuvant treatment course? These are all important directions for future exploration, and there are currently no definitive answers.

Second, all patients enrolled in INTerpath-001 had cutaneous melanoma, whereas acral and mucosal melanoma are more common among Asian patients. These subtypes differ considerably in their tumor biology. Compared with cutaneous melanoma, acral and mucosal melanoma generally have a lower tumor mutational burden (TMB), fewer neoantigens, and potentially more pronounced immunosuppressive tumor microenvironments.

Therefore, we need to investigate whether mRNA vaccines can effectively overcome the immunosuppressive microenvironment in acral and mucosal melanoma, activate tumor-specific immune responses, and subsequently improve event-free survival (EFS) and recurrence-free survival (RFS).

Another consideration comes from the data presented by Professor Georgina Long. More than 30 neoantigens were included in a relatively high proportion of vaccine products in the study. By contrast, patients with acral and mucosal melanoma may have an average of only approximately 10 neoantigens, potentially reducing the number of target antigens that can be incorporated into the vaccine. Whether mRNA vaccines can achieve similarly favorable efficacy in patients with fewer neoantigens is therefore an important question.

Thus, while congratulating the field on this breakthrough with personalized mRNA vaccines in cutaneous melanoma, we must also recognize the new challenges facing Chinese melanoma researchers. How can this innovative treatment strategy be made effective in acral and mucosal melanoma? How can we address the limited number of neoantigens and the immunosuppressive tumor microenvironment? These questions require answers through future clinical research and represent important research priorities for Chinese melanoma investigators.


INTerpath-001 Study Overview

Study Title

LBA1: INTerpath-001: Phase III Study of the mRNA-Based Individualized Neoantigen Therapy (INT) Intismeran Autogene (Intismeran) Plus Pembrolizumab Versus Pembrolizumab Alone for the Adjuvant Treatment of Resected Stage IIB–IV Melanoma

Methods

INTerpath-001 was an international, multicenter, randomized, double-blind Phase III clinical trial. A total of 1,137 patients with malignant melanoma classified as Stage IIB–IV according to the 8th edition of the AJCC staging system were randomized across 157 centers worldwide.

All patients had undergone surgical resection, had not previously received systemic treatment for melanoma, and were required to have tumor samples suitable for next-generation sequencing (NGS) and vaccine production.

Patients were randomized in a 2:1 ratio to receive either:

  • Combination group: Intismeran plus pembrolizumab;
  • Monotherapy group: Placebo plus pembrolizumab.

Pembrolizumab was initiated after randomization and within 13 weeks following surgery. Intismeran was administered once manufacturing was complete, with treatment initiation ranging from Day 22 of Cycle 1 to Day 1 of Cycle 4.

The primary endpoint was investigator-assessed RFS. Key secondary endpoints included DMFS and OS.

The intention-to-treat (ITT) population included all randomized patients, while the modified intention-to-treat (mITT) population included patients who received at least one dose of their assigned study treatment.

Results

A total of 1,749 patients were screened, of whom 1,137 were randomized: 757 to the combination group and 380 to the monotherapy group. Baseline characteristics were balanced between the two groups, with most patients having Stage III disease.

Neoantigens were successfully identified in 91% of patients, with up to 34 neoantigens identified per patient. The manufacturing success rate for intismeran in the combination group exceeded 99%. The median time to first dose was 64 days after randomization, and the median number of doses administered was nine.

Primary endpoint: RFS

The primary RFS analysis showed a significant improvement in the combination group compared with pembrolizumab monotherapy.

In the ITT population, the 24-month RFS rate was 82.2% versus 70.0%, representing a 42% reduction in the risk of recurrence or death (HR 0.58, 95% CI: 0.45–0.75, P<0.001).

Key secondary endpoint: DMFS

The DMFS analysis also demonstrated a significant advantage for the combination group.

In the ITT population, the 24-month DMFS rate was 88.5% versus 80.2%, corresponding to a 38% reduction in the risk of distant metastasis or death (HR 0.62, 95% CI: 0.45–0.85, P=0.002).

In the mITT population, the 24-month DMFS rate was 90.1% versus 80.7%, representing a 45% reduction in the risk of distant metastasis or death (HR 0.55, 95% CI: 0.40–0.77).

Prespecified subgroup analyses showed a consistent trend favoring combination treatment across subgroups, regardless of disease stage or risk level.

OS data remain immature, and follow-up is ongoing.

Safety

The incidence of Grade ≥3 treatment-related adverse events (TRAEs) was 14.2% in the combination group and 13.4% in the monotherapy group.

Two treatment-related deaths occurred in the combination group. However, both occurred before the first vaccine dose and were attributed to pembrolizumab.

Among all adverse events, fever, injection-site pain, and injection-site erythema were more common in the combination group than in the monotherapy group. Most were Grade 1–2 and could be controlled with routine symptomatic management. The addition of intismeran did not increase the incidence of pembrolizumab-related adverse events.

Conclusions

In the adjuvant treatment of patients with resected high-risk Stage IIB–IV melanoma, the personalized mRNA cancer vaccine intismeran combined with pembrolizumab significantly improved RFS and DMFS. The regimen demonstrated favorable tolerability and the feasibility of large-scale global manufacturing, establishing an important milestone in the development of personalized cancer vaccines.


Article content

Interviewee: Professor Jun Guo